Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | PRKCB | P05771 | 2/20 | 0.41 |
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7011009 | 0.82 | SIRT2 (0.47) | SMN1; SMN2HTTSIRT2SIRT1PRKCB | |
| SCHEMBL7004902 | 0.79 | CAMK2D (0.56) | SMN1; SMN2MAPK1SIRT2SIRT1PRKCB | |
| SCHEMBL7006894 | 0.79 | SIRT2 (0.41) | SMN1; SMN2MAPK1SIRT2SIRT1PRKCB | |
| SCHEMBL7010672 | 0.75 | SIRT2 (0.48) | MAPK1SIRT2SIRT1PRKCBPRKCA | |
| Trifluoroacetic Acid SCHEMBL7008461 | 0.74 | CAMK2D (0.49) | CAMK2DPIM1CDK4PRKACAPRKACG | |
| SCHEMBL8520286 | 0.73 | HSP90AA1 (0.54) | SIRT2SIRT1MEN1KMT2AMAPT | |
| 3-Phenylindole SCHEMBL84056 | 0.68 | IMPDH2 (0.71) | NT5ESMN1; SMN2MAPK1SIRT2PRKCB | |
| 3-Phenylindole SCHEMBL29609072 | 0.68 | IMPDH2 (0.71) | NT5ESMN1; SMN2MAPK1SIRT2PRKCB | |
| SCHEMBL18392164 | 0.68 | ESR1 (0.54) | NT5ESMN1; SMN2MAPK1HPGDHTT | |
| SCHEMBL6976408 | 0.68 | MEN1 (0.40) | SMN1; SMN2SIRT2SIRT1PRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042317-B1 | Indole derivatives as PKC-inhiboitors | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | EP | claimed |
| US-6337342-B1 | ARYLIMIDAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-01-08 | — | — | US | claimed |
| EP-1347978-A1 | NOVEL SUBSTITUTED IMIDAZOTRIAZINONES AS PDE II-INHIBITORS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-20030134886-A1 | Pharmaceutically active compounds | ASTRAZENECA AB, A SWEDISH CORPORATION | 2003-07-17 | — | — | US | disclosed |
| EP-1042317-B1 | Indole derivatives as PKC-inhiboitors | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| US-6492409-B1 | SUCH AS 5-(1-(3-AMINOPROPYL)-3-INDOLYL)-1-(3-INDOLYL)-1,3-DIHYDROIMIDAZOL-2-ONE; PROTEIN KINASE C INHIBITORS; HIGH SOLUBILITY; REDUCED COLOR; TREATING INFLAMMATORY AND/OR IMMUNOLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| WO-2002050078-A1 | NOVEL SUBSTITUTED IMIDAZOTRIAZINONES AS PDE II-INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-27 | — | — | WO | disclosed |
| EP-1192150-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | AstraZeneca AB (SE) | 2002-04-03 | — | — | EP | disclosed |
| US-6337342-B1 | ARYLIMIDAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-01-08 | — | — | US | disclosed |
| WO-2000078750-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-12-28 | — | — | WO | disclosed |
| EP-1042317-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | AstraZeneca AB (SE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032483-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134886-A1 | Pharmaceutically active compounds | HTR3C, HTR6, CNR1 | NT5E 3050/4885SMN1; SMN2 3492/4885MAPK1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.